The impact of sertraline on psychomotor performance.
BACKGROUND
Aircrew receiving treatment for depression are grounded during treatment and follow-up observation, generally amounting to at least 1 yr. Selective serotonin re-uptake inhibitors (SSRls) offer new treatment options for depression, of which sertraline (Zoloft) has the least imposing side-effect profile. There has been considerable interest in the possibility of returning aircrew to restricted flying duties once stablized on an SSRI with resolution of depression. This study was undertaken to determine whether or not sertraline effects psychomotor performance.


METHODS
There were 19 volunteer non-depressed subjects (12 men and 7 women) who were assessed for psychomotor performance during placebo and sertraline treatment, in a double-blind cross-over protocol in counter-balanced order. Each treatment arm lasted 5 wk and involved ingesting one capsule each morning. The daily sertraline dose was 50 mg during week 1, 100 mg during week 2, and 150 mg during weeks 3, 4, and 5. Subjects completed a drug side-effect questionnaire and were tested on two psychomotor test batteries once per week, on the same weekday, at the same time of day throughout each 5-wk treatment period.


RESULTS
There was no significant effect of sertraline on serial reaction time, logical reasoning, serial subtraction, or multitask performance. With respect to drug side effects, there was a main effect of drugs on "getting to sleep" (p < 0.002), "awakenings" (p < 0.007), "returning to sleep" (p < 0.001), "dry mouth" (p < 0.016), "nausea" (p < 0.001), "diarrhea" (p < 0.026), "tremors" (p < 0.005), and "sweating" (p < 0.016), as well as a drug x trials interaction for "drowsiness" (p < 0.012), "libido" (p < 0.039), and "difficulty with ejaculation" (p < 0.001). There was no effect of sertraline on dizziness.


CONCLUSIONS
While we found some of the expected side effects due to sertraline, there was no effect on psychomotor performance. These findings support the possibility of selected use in aircrew and should be helpful in the ongoing aeromedical discussion about this evolving issue.
Paul
Michel A
MA
Defence and Civil Institute of Environmental Medicine, North York, Ontario, Canada. paul@dicem.dnd.ca
Gray
Gary
G
Lange
Marvin
M
D000328:Adult; D000337:Aerospace Medicine; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects*; D011930:Reaction Time / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D020280:Sertraline / Q000009:adverse effects / Q000494:pharmacology*
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline